The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin

• Main Authors: Xiaoyu Fu (Author), Mathew Eggert (Author), Sieun Yoo (Author), Nikhil Patel (Author), Juming Zhong (Author), Ian Steinke (Author), Manoj Govindarajulu (Author), Emine Akyuz Turumtay (Author), Shravanthi Mouli (Author), Peter Panizzi (Author), Ronald Beyers (Author), Thomas Denney (Author), Robert Arnold (Author), Rajesh H. Amin (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Doxorubicin (DOX) is an anthracycline cancer chemotherapeutic that exhibits cumulative dose-limiting cardiotoxicity and limits its clinical utility. DOX treatment results in the development of morbid cardiac hypertrophy that progresses to congestive heart failure and death. Recent evidence suggests...